BlueSphere Bio is a private, well-funded T cell therapy company focused on the discovery of novel TCR-based cell therapies to treat hematologic malignancies and solid tumors
BlueSphere’s three platforms work synergistically to efficiently deliver high-potency TCRs and antigens in under 3 weeks per platform.
TCXpress™ is a proprietary high-throughput and efficient TCR capture, expression, and functional screening platform.
BSB has an automation suite with diverse capabilities and our established protocols decreased hands-on time.
Our team overcame a multitude of challenges automating plasmid purification and 6-well transfection protocols.
Automated plasmid purification produced sufficient yield for downstream assays and has up to 85% human-time savings.
Automated library production produced 89% of median TCR expression post-selection and has an estimated 63% human-time savings.
Innovating in the field of precision medicine is critical to build panels of TCRs that can treat large populations of people.